Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
Rhea-AI Summary
Insmed (Nasdaq: INSM) announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m. ET. A live webcast and 30-day replay will be available on Insmed's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – INSM
In the May 27 session, INSM declined 2.27%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Positive | -23.4% | Strong revenue growth and reiterated 2026 guidance but shares fell sharply. |
| May 06 | Awareness campaign launch | Positive | -23.4% | Bronchiectasis education initiative with Ty Pennington to boost disease awareness. |
| May 04 | Respiratory data presentations | Positive | +5.1% | Multiple ATS 2026 abstracts including late-breaking Phase 3b ENCORE results. |
| Apr 30 | Investor conferences May | Neutral | +1.0% | Planned presentations at BofA and RBC healthcare conferences with webcasts. |
| Apr 23 | Earnings call announcement | Neutral | -0.5% | Scheduled Q1 2026 results release and business update conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions: positive operational and clinical updates sometimes drew sharp selloffs, while data and conference news occasionally aligned with modest gains.
Over the past two months, INSM reported Q1 2026 results with strong BRINSUPRI and ARIKAYCE growth, yet the stock fell 23.41%. Awareness and respiratory data announcements in early May showed both a 5.07% gain and flat-to-negative moves, indicating uneven reactions. Prior investor conference notices in late April had a small 0.96% uptick. Against this backdrop, today’s Goldman Sachs conference appearance fits a pattern of frequent investor outreach alongside substantial clinical and commercial updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. This webcast will be archived for a period of 30 days following the conclusion of this live event.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue.
Headquartered in
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com
Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-2026-goldman-sachs-annual-global-healthcare-conference-302782306.html
SOURCE Insmed Incorporated